MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS).
GBS is the leading cause of life-threatening bacterial infections in newborn babies affecting some 8,000 babies annually in Europe and the US. GBS infections in utero may result in premature delivery or stillbirth, and in the newborn infant, pneumonia, septicaemia and meningitis leading to severe morbidity, mortality or life-long disabilities. The National Institute of Health of the US has identified prevention of GBS in newborns as a major vaccine objective, but so far no approved or universally useful vaccine exists. A general vaccine effective against relevant strains of GBS is poised to have both a great medical and pharmacoeconomical impact if administered universally to pregnant women.